Global Anticoagulant Market 2017-2021

Overview of the global anticoagulant market

Technavio’s market research analyst predicts the global anticoagulant market to grow steadily at a CAGR of above 7% by 2021. One of the primary drivers for this market is the rise in demand for novel oral anticoagulants (NOACs). NOACs target either thrombin or factor Xa to prevent and treat thrombosis. They show quick action and do not require continuous monitoring. They also have better safety and efficacy profiles when compared with conventional therapies such as warfarin. Moreover, the introduction of anticoagulant antidotes in 2015 such as idarucizumab into the market is expected to increase the acceptance of NOACs, as the risk of bleeding will be eradicated. Consequently, this will propel the growth of the global anticoagulant market during the forecast period.

In terms of geography, the Americas accounted for the maximum market share during 2016 and will continue to dominate the market for the next few years. The Americas market is growing at a significant growth pace with the introduction of NOACs. The warfarin showed high growth when compared with the oral anticoagulant. However, the revenue generated from the sales of warfarin is low due to the availability of generics, which are available at significantly lower prices. With vitamin K antagonists taking over the share of factor Xa inhibitors and DTIs, the Americas is expected to dominate to global anticoagulant market for the coming few years.

Competitive landscape and key vendors

The global anticoagulant market is highly competitive due to the presence of several international and regional vendors. The market has observed a high growth because of the increase in usage of NOACs and the growing number of surgeries worldwide. This has influx intense competition among the players in the NOACs market, which is emerging in the anticoagulant market. Also, the growing focus of established vendors in the emerging economies will likely change the market dynamics in the next four years.

Leading vendors in the market are –

• Bayer HealthCare
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Daiichi Sankyo
• Johnson & Johnson
• Sanofi

Other prominent vendors in the anticoagulant market include AstraZeneca, Eli Lilly, Keryx Biopharmaceuticals, LEO Pharma, Pfizer, and The Medicines Company.

Segmentation by ROA and analysis of the anticoagulant market

• Oral
• Injectable

During 2016, the oral anticoagulant drugs dominated the anticoagulant market and accounted for a major part of the overall market share. Factors such as high patience adherence, cost-effectiveness, and painless treatment are the key contributors to the dominance of this segment in the global market.

Segmentation by drug class and analysis of the anticoagulant market

• Factor Xa inhibitors
• DTIs
• Heparin
• Vitamin K antagonists

In this market study, analysts have estimated factor Xa inhibitors segment to dominate the anticoagulant market during the forecast period. With major drug approvals, such as rivaroxaban (XARELTO), edoxaban (SAVAYSA), and apixiban (ELIQUIS) the factor Xa inhibitors are expected to grow its market share in the next four years.

Key questions answered in the report include

• What will the market size and the growth rate be in 2021?
• What are the key factors driving the global anticoagulant market?
• What are the key market trends impacting the growth of the global anticoagulant market?
• What are the challenges to market growth?
• Who are the key vendors in the global anticoagulant market?
• What are the market opportunities and threats faced by the vendors in the global anticoagulant market?
• Trending factors influencing the market shares of the Americas, APAC, and EMEA.
• What are the key outcomes of the five forces analysis of the global anticoagulant market?

Technavio also offers customization on reports based on specific client requirement.

Related reports

• Global Human Albumin Market 2016-2020  
• Global Blood Coagulation Analyzer Market 2016-2020 
• Global Tissue Heart Valves Market 2016-2020